Transcriptional control of viral gene therapy by cisplatin

Journal of Clinical Investigation

Volumn 110, Issue 3, 2002, Pages 403-410

  Park, James O ^a   Lopez, Carlos A ^a   Gupta, Vinay K ^a   Brown, Charles K ^a   Mauceri, Helena J ^a   Darga, Thomas E ^a   Manan, Abdullah ^a   Hellman, Samuel ^a   Posner, Mitchell C ^a   Kufe, Donald W ^b   Weichselbaum, Ralph R ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; EARLY GROWTH RESPONSE FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; DNA DAMAGE; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSCRIPTION REGULATION; VIRAL GENE THERAPY;

EID: 0036322088     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215548     Document Type: Article

References (40)

1. Gene therapy
2. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
3. Molecular targeting of gene therapy and radiotherapy
4. Cancer gene and oncolytic virus therapy
5. Targeted adenoviral vectors for cancer gene therapy
6. Lipoplexes and tumours. A review
7. Direct gene transfer to mouse melanoma by intratumor injection of free DNA
8. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
9. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions
10. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
11. Conditional gene targeting for cancer gene therapy
12. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
13. Transcriptionally targeted in vivo gene therapy for carcinoembrionic antigen-producing adenocarcinoma
14. Spatial and temporal control of gene therapy using ionizing radiation
15. Tumor necrosis factor (TNF)
16. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level
17. Toxic effect of tumor necrosis factor on tumor vasculature in mice
18. A novel domain within the 55 kd TNF receptor signals cell death
19. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro
20. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
21. Possible mechanisms for turnout cell sensitivity to TNF-alpha and potential therapeutic applications
22. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium
23. Tumor production of angiostatin is enhanced after exposure to TNF-alpha
24. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase 1 and pharmacologic study
25. Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin
26. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells
27. Cyrokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan
28. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
29. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft
30. Reactive oxygen intermediares target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation
31. Cellular rhiols and reactive oxygen species in drug-induced apoptosis
32. Cisplatin and its analogues
33. Mechanisms of resistance to cisplatin
34. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: An Eastern Cooperative Oncology Group Study (PB586)
35. A phase I trial of recombinant human tumor necrosis Factor and interferon-gamma: Effects of combination cytokine administration in vivo
36. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors
37. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis Factor and melphalan For the treatment of unresectable heparic malignancies
38. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion
39. Radiation induction of immediate early genes: Effectors of the radiation-stress response
40. Transfer of genes to humans: Early lessons and obstacles to success